[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl](4-hydroxyphenyl)-methanone

CAS : 177744-96-6

Ref. 3D-IH44805

Informations sur le produit

• Nom: [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl](4-hydroxyphenyl)-methanone
• Synonymes: Raloxifene impurity DLY 88074

Description

MDM2 inhibitors are a class of cancer drugs that inhibit the activity of MDM2, which is an oncoprotein that prevents the degradation of p53. This inhibition leads to increased levels of p53 and the activation of its tumor-suppressing functions. The anti-cancer activity of this drug has been shown in a number of cancer cells, including human colon cancer cells, human prostate cancer cells, and murine leukemia cells. Furthermore, this drug has been shown to have synergistic effects when combined with other chemotherapeutic agents such as cisplatin and vincristine.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 362.4 g/mol
• Formule: C₂₁H₁₄O₄S
• Degré de pureté: Min. 95%
• InChI: InChI=1S/C21H14O4S/c22-14-5-1-12(2-6-14)20(25)19-17-10-9-16(24)11-18(17)26-21(19)13-3-7-15(23)8-4-13/h1-11,22-24H
• Code InChI: InChIKey=CTMKIRXPVZYQJP-UHFFFAOYSA-N
• SMILES: O=C(c1ccc(O)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12